<DOC>
	<DOCNO>NCT03011060</DOCNO>
	<brief_summary>This study evaluate whether sequential neo-adjuvant chemotherapy plus surgery follow Capecitabine could achieve additional benefit traditional postoperative chemotherapy . In study group , patient achieve pathological complete response ( pCR ) receive sequential neo-adjuvant chemotherapy follow Capecitabine . In control group , patient treat postoperative adjuvant chemotherapy .</brief_summary>
	<brief_title>Sequential Neo-adjuvant Chemotherapy Followed Capecitabine Vs . Conventional Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>Neo-adjuvant chemotherapy ( NAC ) standard treatment locally advance breast cancer ( LABC ) . By down-staging LABC , NAC able make inoperable case operable well make breast conserving surgery option patients.Neo-adjuvant chemotherapy widely use operable breast cancer since provide critical information chemotherapy response . However , 15 % 20 % patient benefit Neo-adjuvant chemotherapy achieve pCR . Although obtain information chemotherapy response rest patient receive Neo-adjuvant chemotherapy , still controversies information use treatment . Therefore , problem need resolve patient benefit information Neo-adjuvant chemotherapy provide whether Neo-adjuvant chemotherapy replace conventional adjuvant chemotherapy . Our study aim make Neo-adjuvant chemotherapy benefit patient . Registered patient stage Ⅰ- Ⅲ A breast cancer randomly split two group ( study group control group ) .In study group , patient achieve pCR follow 5 year patient achieve pCR neo-adjuvant chemotherapy treat Capecitabine 8 cycle surgery . On hand , patient control group accept surgery conventional adjuvant chemotherapy . Follow-up study last 5 year . DFS OS compare two group . This study provide important basis method treatment patient neo-adjuvant chemotherapy . It discuss whether neo-adjuvant chemotherapy could replace conventional adjuvant chemotherapy become new standard breast cancer treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Pathologically confirmed unilateral invasive carcinoma ( pathological type ) ; 2 . No gross microscopic residual tumor resection ; 3 . Clinical stage Ⅰstage Ⅲ A , absolute surgical contraindication ; 4 . Eastern Cooperative Oncology Group ( ECOG ) score ≤1 ; 5 . Accepting adjuvant chemotherapy within 15 day surgery ; 6 . No peripheral neuropathy ; 7 . Normal bone marrow organ function : 1 . Bone marrow function : ANC≥1500/mm3，PLT≥100000/mm3，HGB≥8g/dl 2 . Renal function : serum creatinine≤1.5 time upper limit normal ( ULN ) , Liver function : total bilirubin ≤1.5 time upper limit normal，AST≤2.5 time upper limit normal，alanine aminotransferase ( ALT ) ≤2.5 time upper limit normal 3 . Cardiac function : LVEF≥50 % 8 . Signed informed consent form . 1 . Patients history oral fluorouracil chemotherapy Chinese medicine treatment ; 2 . Patients organ dysfunction : 1 . Renal function : serum creatinine &gt; 1.5 time upper limit normal 2 . Liver function : total bilirubin &gt; 1.5 time upper limit normal，AST &gt; 1.5 time upper limit normal , alanine aminotransferase ( ALT ) &gt; 1.5 time upper limit normal alkaline phosphatase ( ALP ) &gt; 2.5 time upper limit normal 3 . Cardiac function：LVEF &lt; 50 % ; 3 . Human epidermal growth factor receptor2 ( HER2 ) positive patient receive Herceptin treatment leave ventricular ejection fraction ( LVEF ) less 55 % ; 4 . Patients allergic docetaxel , capecitabine , epirubicin cyclophosphamide ; 5 . Patients severe systemic disease and/or uncontrollable infection ; 6 . Patients previous malignancy , include contralateral breast cancer ; 7 . Patients severe cardiovascular cerebrovascular disease ( i.e . Unstable angina , chronic cardiac failure , uncontrollable high blood pressure &gt; 150/90 mmhg , myocardial infarction cerebrovascular accident ) history within 6 month randomization ; 8 . Pregnant lactating woman . 9 . Patients cognitive psychological impairment well understand test program stand side effect , result suspension trial program followup ; 10 . Patients without personal freedom independent civil capacity .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>neo-adjuvant chemotherapy</keyword>
	<keyword>pathological complete response</keyword>
	<keyword>Neoadjuvant Therapy</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Chemotherapy , Adjuvant</keyword>
</DOC>